Our research goal is to understand the molecular and cellular events required for pancreatic β - cell regeneration, and apply this knowledge towards the development
of cell replacement therapies for diabetes.
Dr. Paul Laikind, ViaCyte's president and chief executive officer said, «Our comprehensive and growing intellectual property portfolio helps to establish ViaCyte as a leading company in the
area of cell replacement therapy and regenerative medicine.